About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 172 record(s)
Req # A-2022-001369
Adverse Drug Reaction (ADR). Report number: E2B_05880482.Organization: Health Canada
February 2023
Req # A-2022-001372
Adverse Drug Reaction (ADR). Report number: (ADR): 001017052.Organization: Health Canada
February 2023
Req # A-2018-000066
All records sent, received or transferred by Stakeholder Engagement, Cannabis Legalization and Regulation Branch, Health Canada from March 12, 2018 to April 11, 2018 inclusively.Organization: Health Canada
February 2023
Req # A-2018-000318
New drug submissions filed by Samsung Bioepis Co. Ltd. for its adalimumab product named HADLIMA. The NDS nos. are 203250 and 203292. It is our understanding that all applications initiated by Abbvie Corporation and Abbvie Biotechnology Ltd. prohibiting the Minister of Health from issuing notices of compliance to Bioepis for these new drug submissions have been discontinued. Module 1, excluding the following: 1.2.3, 1.2.4.2, 1.2.5, 1.2.8, 1.3, 1.6, 1.7.Organization: Health Canada
February 2023
Req # A-2018-001450
All documents regarding PACR2005-08- Proposed Acceptability for Continued Registration Re-Evaluation of Strychnine for the time period between 1992 and 2005.Organization: Health Canada
February 2023
Req # A-2019-000972
All documents related to the regulation, marketing, sale and health effects of nicotine e-cigarettes/vaping products in Canada in 2019 in connection with the newly discovered pulmonary illness related to vaping or believed to be related to vaping in the United States of America and Canada.Organization: Health Canada
February 2023
Req # A-2020-000061
All information related to the low- to medium-risk claims about the immune function on Natural Product Number (NPN) 80041741 Jamieson’s Vitamin D product.Organization: Health Canada
February 2023
Req # A-2020-000196
Provide the dosage form(s) and dosage strength(s) of cyclosporine in each Abbreviated New Drug Submission Health Canada has received for cyclosporine that are not approved.Organization: Health Canada
February 2023
Req # A-2020-000400
The most recent draft copies of memorandum, briefing notes, reports, or other documents concerning data, recommendations and/or policy measures regarding asymptomatic transmission of COVID-19. All records created/dated February 1st, 2020 or later.Organization: Health Canada
February 2023
Req # A-2020-001931
Once the devices were approved, all electronic documents regarding why the identified products are no longer authorized for sale in Canada, potential recalls/stop-sales, reports, and any revisions made to the products.Organization: Health Canada
February 2023